Rigel Pharmaceuticals has enrolled the first subject in a Phase I trial of its oral spleen tyrosine kinase (SYK) inhibitor, ...

Rigel Pharmaceuticals (NASDAQ:RIGL – Get Free Report)‘s stock had its “buy” rating reiterated by equities research analysts at HC Wainwright in a note issued to investors on Wednesday,Benzinga reports ...

Research analysts at Cantor Fitzgerald issued their FY2025 earnings per share (EPS) estimates for Rigel Pharmaceuticals in a report released on Tuesday, January 21st. Cantor Fitzgerald analyst K.

Rigel Pharmaceuticals (RIGL) announced the first patient has been enrolled in a Phase 1 study evaluating the safety and tolerability of ...

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced the first patient has been enrolled in a Phase 1 study evaluating ...

While Rigel is still determining final results for the fourth quarter of 2024, the company expects to report fourth quarter total revenue of ...

KFDA approves immune thrombocytopenia treatment Tavalisse from Rigel Pharmaceuticals KFDA greenlights Tavalisse, a ...

(RTTNews) - Rigel Pharmaceuticals, Inc. (RIGL) said it expects to report fourth quarter total revenue of $57.6 million, compared to $35.8 million for the same period of 2023. Rigel expects to ...

Rigel Pharmaceuticals has shown significant growth, particularly from the acquisition of pralsetinib, leading to a 46% improvement in stock valuation since April. Rigel's pipeline includes three ...

SOUTH SAN FRANCISCO, Calif., Jan. 13, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today ...